PofoliaPofolia ile paylaşıldı

Journal of Industrial Microbiology & Biotechnology· 2016Q2

Doğal ürün keşfi: geçmiş, bugün ve gelecek

Natural product discovery: past, present, and future

Leonard Katz, Richard H. Baltz

Kısa özet

Genom dizileme, mikropların daha önce bilinenin yaklaşık 10 katı kadar ikincil metabolit üretebildiğini ortaya koyuyor ve mikrobiyal genom madenciliği yoluyla yeni ilaç keşfini mümkün kılıyor.

Yapay zekâ ile başlık ve abstract'tan üretildi; tam metin okunmaz.

Ana noktalar

  • Genom dizilemesiyle ortaya çıkan mikroplar, daha önce bilinenin yaklaşık on katı kadar ikincil metabolit üretebilir.
  • Aktinomisetler, bir bakteri grubu, her biri 30-50 ikincil metabolit üretebilir.
  • Genom dizileme maliyetinin düşmesi, yeni doğal ürün keşfi için 'biyosentetik karanlık maddeyi' belirlemeyi fizibil hale getiriyor.
  • Biyoenformatik ve omik teknolojilerindeki ilerlemeler, mikrobiyal genom madenciliği için kritik öneme sahiptir.

Yapay zekâ ile başlık ve abstract'tan üretildi; tam metin okunmaz.

Özet (abstract)

Microorganisms have provided abundant sources of natural products which have been developed as commercial products for human medicine, animal health, and plant crop protection. In the early years of natural product discovery from microorganisms (The Golden Age), new antibiotics were found with relative ease from low-throughput fermentation and whole cell screening methods. Later, molecular genetic and medicinal chemistry approaches were applied to modify and improve the activities of important chemical scaffolds, and more sophisticated screening methods were directed at target disease states. In the 1990s, the pharmaceutical industry moved to high-throughput screening of synthetic chemical libraries against many potential therapeutic targets, including new targets identified from the human genome sequencing project, largely to the exclusion of natural products, and discovery rates dropped dramatically. Nonetheless, natural products continued to provide key scaffolds for drug development. In the current millennium, it was discovered from genome sequencing that microbes with large genomes have the capacity to produce about ten times as many secondary metabolites as was previously recognized. Indeed, the most gifted actinomycetes have the capacity to produce around 30-50 secondary metabolites. With the precipitous drop in cost for genome sequencing, it is now feasible to sequence thousands of actinomycete genomes to identify the "biosynthetic dark matter" as sources for the discovery of new and novel secondary metabolites. Advances in bioinformatics, mass spectrometry, proteomics, transcriptomics, metabolomics and gene expression are driving the new field of microbial genome mining for applications in natural product discovery and development.

Yazarların özeti; kaynağından alınmıştır. Journal of Industrial Microbiology & Biotechnology, 2016 · DOI ↗

ÇıkarımlarPremium
Makaleye SorÜcretsiz hesapla

Ücretsiz hesapla devam et

Makaleye Sor ile bu makaleye günde 3 soru ücretsiz; makaleyi kaydet, kaynakçasını al, ilgi alanına göre her gün yeni özetler. Çıkarımlar Premium.

Web'de ücretsiz devam et

Google ya da Apple hesabınla giriş; kart istemez. Bu makaleye geri dönersin.

Telefonda:

Alan: Farmakoloji (Tıp)

PharmacologyMedicine